Valuation : Mesoblast Limited

Market Cap 3.04B 2.17B 1.88B 1.76B 1.61B 3.02B 206B 20.86B 8.12B 105B 8.16B 7.99B 348B P/E 2027 *
-162x
P/E 2028 * 10.5x
Enterprise Value 3.14B 2.24B 1.94B 1.82B 1.66B 3.12B 213B 21.53B 8.38B 108B 8.43B 8.24B 359B EV / Sales 2027 *
11.5x
EV / Sales 2028 * 4.71x
Free-Float
63.68%
Yield 2027 *
-
Yield 2028 * -
1 day+1.28%
1 week+0.42%
Current month+0.42%
1 month+16.75%
3 months+15.61%
6 months+14.49%
Current year-12.87%
1 week 2.25
Extreme 2.25
2.54
1 month 2.01
Extreme 2.01
2.58
Current year 1.88
Extreme 1.88
3.31
1 year 1.88
Extreme 1.88
3.31
3 years 0.26
Extreme 0.255
3.37
5 years 0.26
Extreme 0.255
3.37
10 years 0.26
Extreme 0.255
5.7
Manager TitleAgeSince
Chief Executive Officer 69 23/03/2011
Director of Finance/CFO 59 17/11/2025
Chief Tech/Sci/R&D Officer - 11/03/2026
Director TitleAgeSince
Director/Board Member 69 01/01/2007
Director/Board Member 75 15/04/2013
Director/Board Member 78 06/03/2014
Date Insider Type Main position Quantity % Market Cap. Importance
19/08/26 Free

Director

875,000 0.0674%
17/07/26 Exercice

Founder

1,885,334 0.1456%
17/07/26 Exercice

Founder

-1,885,334 0.1456%
Change 5-day change 1-year change 3-year change Capi.($)
+1.28%+0.42%+17.33%+398.95% 2.17B
+0.26%-1.46%+2.77%+16.94% 49.74B
+2.09%-0.71%+452.73%+498.77% 44.98B
-1.09%-0.41%+35.40%+15.17% 42.52B
-0.26%-4.71%+17.19%+71.67% 40.78B
-0.48%-0.84%+16.25%+49.80% 32.89B
-1.06%+2.87% - - 17.09B
-1.81%-5.02%+22.65%+113.24% 16.28B
-0.17%-1.90%+16.35%+25.73% 14.4B
-2.05%-5.14%+72.89%+34.69% 13.48B
Average -0.54%-2.24%+72.62%+136.11% 27.43B
Weighted average by Cap. -0.49%-2.26%+96.67%+124.52%

Financials

2027 *2028 *
Net sales 273M 195M 168M 158M 144M 271M 18.51B 1.87B 728M 9.42B 732M 716M 31.22B 560M 401M 346M 325M 296M 557M 38.05B 3.85B 1.5B 19.36B 1.51B 1.47B 64.19B
Net income -2.2M -1.57M -1.36M -1.28M -1.16M -2.19M -149M -15.08M -5.87M -75.9M -5.9M -5.78M -252M 204M 146M 126M 118M 108M 203M 13.83B 1.4B 544M 7.03B 547M 535M 23.32B
Net Debt 97.67M 69.88M 60.28M 56.71M 51.66M 97.14M 6.63B 670M 261M 3.37B 262M 257M 11.19B -398M -285M -246M -231M -211M -396M -27.04B -2.73B -1.06B -13.75B -1.07B -1.05B -45.61B
Logo Mesoblast Limited
Mesoblast Limited is an Australia-based biotechnology company. The Company is engaged in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The Company has developing a range of late-stage product candidates, derived from its first and second generation proprietary mesenchymal lineage cell therapy technology platforms therapies for distinct indications. The Company's Ryoncil (remestemcel-L-rknd) is an allogeneic bone marrow-derived mesenchymal stromal cell (MSC) therapy. Its other product candidate is Revascor (rexlemestrocel-L). Rexlemestrocel-L is second generation mesenchymal lineage precursor cell product platform and is in late-stage development for treatment of: Chronic heart failure (CHF) and Chronic low back pain (CLBP) due to degenerative disc disease. The two products have been commercialized in Japan and Europe by the Company's licensees.
Employees
108
Date Price Change Volume
02/09/26 A$2.370 +1.28% 3,362,677
01/09/26 A$2.340 -0.85% 2,391,767
31/08/26 A$2.360 -4.07% 3,668,124
28/08/26 A$2.460 +2.07% 4,695,758
27/08/26 A$2.410 +2.12% 3,302,336
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
2.340AUD
Average target price
3.905AUD
Spread / Average Target
+66.88%

Quarterly revenue - Rate of surprise